Cure My Disease

Don't miss your cure!

 Log in / Sign up

Same-Day HIV treatment: a new weapon against stigma?

NCT ID NCT07053514

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers in Peru are testing whether starting antiretroviral therapy on the same day as diagnosis can reduce the stigma that people with HIV face. The study involves developing a same-day treatment protocol with input from HIV experts, then piloting it with patients and their clinicians. The goal is to see if this approach lowers both patient-reported stigma and provider bias, potentially making HIV care more welcoming.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Same-day antiretroviral therapy (SD-ART) protocol
What this could lead to
If successful, this could make starting HIV treatment faster and less stigmatizing, improving care for key affected populations.
What could go wrong
This is a small pilot study, so results may not apply broadly. Stigma is complex and may not change with timing alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 139 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2027

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aim 1: HIV experts will be selected from National Societies of HIV experts according to the following criteria: 1) 18 years old or older; 2) Be an HIV expert, including those from NGOs providing HIV care, and international specialists; 3) Provide informed consent. * Aim 2: * NGT Focus Groups (FG) * Staff members 1. 18 years old or older. 2. Be a clinical staff member at Hospital Dos de Mayo or Patrucco Primary Health Center. 3. Provide informed consent. * PWH receiving HIV care 1. 18 years old or older. 2. Identify as member of a KAP. 3. Receive HIV care at Hospital Dos de Mayo or Patrucco Primary Health. 4. Provide informed consent. * PWH who dropped out of HIV care 1. 18 years old or older. 2. Identify as a member of a KAP. 3. Previously received HIV care at Hospital Dos de Mayo or Patrucco Primary Health but dropped out of care, as identified through patient registries. 4. Provide informed consent. * In-depth interviews * 1\) 18 years old or older. * 2\) Be the director of Hospital Dos de Mayo or Patrucco primary health center or the HIV director at the Ministry of Health * 3\) Provide informed consent * Aim 3: * Clinical Staff Dyadic Surveys * 1\) 18 years old or older. * 2\) Be an HIV provider at Hospital Dos de Mayo or Raul Patrucco Primary Health Center. * 3\) Provide HIV care to one of the 125 PWH * 4\) Provide informed consent. * Patient Dyadic Surveys * 1\) 18 years old or older. * 2\) Identify as a member of a KAP. * 3\) Be newly diagnosed with HIV and eligible for SD-ART based on clinical criteria identified from Aims 1 and 2. * 4\) Provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro de Salud Raul Patrucco Puig

    Lima, Peru

  • Hospital Dos de Mayo

    Lima, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.